Literature DB >> 12138326

Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers.

Alain Mignot1, Michel Guillaume, Muriel Brault, Virginie Gualano, Laurette Millérioux, Karin Göhler, Hans-Jüergen Stahlberg.   

Abstract

The multiple-dose pharmacokinetics and excretion balance of gatifloxacin were evaluated in 42 healthy Caucasian volunteers. Following multiple oral doses of 400 and 600 mg, the pharmacokinetics of gatifloxacin were similar on days 1 and 15, suggesting no therapeutically relevant time-dependent changes in the pharmacokinetics of gatifloxacin at the doses and duration of dosing studied. Gatifloxacin was rapidly absorbed and a favourable elimination half-life of 7-8 h was evaluated. Saliva concentrations were similar to plasma concentrations. The main route of excretion is the urine. After a single dose of 400 mg of gatifloxacin, the recovery in urine was 83% and 5.2% in faeces. Following multiple doses of 400 or 600 mg, the renal excretion was 80 and 77%, respectively. The drug was well tolerated. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138326     DOI: 10.1159/000064915

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

Review 1.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 2.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

5.  Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.

Authors:  Wynand Smythe; Corinne S Merle; Roxana Rustomjee; Martin Gninafon; Mame Bocar Lo; Oumou Bah-Sow; Piero L Olliaro; Christian Lienhardt; John Horton; Peter Smith; Helen McIlleron; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 6.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 7.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.